RU2003123505A - Гепарин со средней молекулярной массой - Google Patents

Гепарин со средней молекулярной массой Download PDF

Info

Publication number
RU2003123505A
RU2003123505A RU2003123505/15A RU2003123505A RU2003123505A RU 2003123505 A RU2003123505 A RU 2003123505A RU 2003123505/15 A RU2003123505/15 A RU 2003123505/15A RU 2003123505 A RU2003123505 A RU 2003123505A RU 2003123505 A RU2003123505 A RU 2003123505A
Authority
RU
Russia
Prior art keywords
heparin
molecular weight
average molecular
factor
activity
Prior art date
Application number
RU2003123505/15A
Other languages
English (en)
Other versions
RU2322245C2 (ru
Inventor
Дитер Вельцель (De)
Дитер ВЕЛЬЦЕЛЬ
Original Assignee
Дитер Вельцель (De)
Дитер ВЕЛЬЦЕЛЬ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дитер Вельцель (De), Дитер ВЕЛЬЦЕЛЬ filed Critical Дитер Вельцель (De)
Publication of RU2003123505A publication Critical patent/RU2003123505A/ru
Application granted granted Critical
Publication of RU2322245C2 publication Critical patent/RU2322245C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Claims (2)

1. Применение гепарина со средней молекулярной массой, составляющей от 10 до 11,5 кДа, для получения лекарственного средства, предназначенного для профилактики и терапии тромботических процессов.
2. Применение по п.1, при котором используют гепарин со средней молекулярной массой, составляющей 10,5 кДа.
RU2003123505/15A 2000-01-10 2000-12-22 Гепарин со средней молекулярной массой RU2322245C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10000602 2000-01-10
DE10000602.7 2000-01-10

Publications (2)

Publication Number Publication Date
RU2003123505A true RU2003123505A (ru) 2005-02-27
RU2322245C2 RU2322245C2 (ru) 2008-04-20

Family

ID=7627036

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003123505/15A RU2322245C2 (ru) 2000-01-10 2000-12-22 Гепарин со средней молекулярной массой

Country Status (9)

Country Link
US (1) US7008933B2 (ru)
EP (2) EP1505079A3 (ru)
AT (1) ATE279929T1 (ru)
AU (1) AU2001230019A1 (ru)
CA (1) CA2434393C (ru)
DE (2) DE10084241D2 (ru)
ES (1) ES2231303T3 (ru)
RU (1) RU2322245C2 (ru)
WO (1) WO2001051525A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
CN101495517B (zh) * 2006-05-25 2012-10-10 莫曼塔医药品有限公司 低分子量肝素及其用途
US9139876B1 (en) * 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US20110076729A1 (en) * 2008-02-20 2011-03-31 Momenta Pharmaceuticals, Inc. Methods of making low molecular weight heparin compositions
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP3348270A1 (en) 2017-01-11 2018-07-18 Fytagoras B.V. Medium molecular weight heparin
EP3581189A1 (en) * 2018-06-14 2019-12-18 Fytagoras B.V. Medium molecular weight heparin for treatment and secondary prevention of ischemic stroke

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687765A (en) * 1983-07-25 1987-08-18 Choay S.A. Method and composition for thrombolytic treatment
EP1192187A1 (en) * 1999-06-30 2002-04-03 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors

Also Published As

Publication number Publication date
RU2322245C2 (ru) 2008-04-20
WO2001051525A1 (de) 2001-07-19
ES2231303T3 (es) 2005-05-16
DE50008363D1 (de) 2004-11-25
DE10084241D2 (de) 2003-02-20
ATE279929T1 (de) 2004-11-15
EP1505079A3 (de) 2005-04-13
EP1252194A1 (de) 2002-10-30
EP1505079A2 (de) 2005-02-09
US20030134823A1 (en) 2003-07-17
CA2434393C (en) 2009-09-15
AU2001230019A1 (en) 2001-07-24
EP1252194B1 (de) 2004-10-20
US7008933B2 (en) 2006-03-07
CA2434393A1 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
Hoffman et al. Cellular interactions in hemostasis
RU2003123505A (ru) Гепарин со средней молекулярной массой
DE60125154D1 (de) Teildesulfatierte glykosaminoglykanderivate mit antiangiogenischer aktivität und ohne antikoagulierender wirkung
MY133897A (en) N-(4-carb-amimidophenyl) glycineamide derivatives
BR0012202A (pt) Composições de heparina de peso molecular médio (mmwh), método de tratamento de uma condição trombótica, método de prevenção da formação de um trombo, método de inibição da formação de trombos, composição farmacêutica, método de tratamento de trombose venosa profunda, método de prevenção de embolia pulmonar, método de preparação e usos de uma composição de mmwh
ATE316384T1 (de) Neue dialysemethode
EA200100966A1 (ru) ЛЕЧЕНИЕ ТРОМБОЗА КОМБИНИРОВАННЫМ ПРИМЕНЕНИЕМ ИНГИБИТОРА ФАКТОРА Xa И АСПИРИНА, АКТИВАТОРА ТКАНЕВОГО ПЛАЗМИНОГЕНА (TPA), АНТАГОНИСТА GPIIB/IIIA, НИЗКОМОЛЕКУЛЯРНОГО ГЕПАРИНА ИЛИ ГЕПАРИНА
FR2790763B1 (fr) Nouvelle masse adhesive hydrocolloide presentant une meilleure resistance a la degradation de sa capacite d'absorption apres radiosterilisation
RU95105983A (ru) Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе
PT1294394E (pt) Produto de associacao compreendendo melagatran e um inibidor de factor xa
Scharrer The need for highly purified products to treat hemophilia B
NO995800L (no) Anvendelse av oligosakkarid for forhindring av blodkoagulering i ekstrakorporeale blodkretser
EP1110556A4 (en) PREVENTIVE DRUGS / AND REMEDIES AGAINST MULTIPLE ORGANS FAILURE
NO20030841L (no) En ny spesifikk mekanisme for inhibering av blodplateadhesjon til kollagen
De Prost Heparin fractions and analogues: a new therapeutic possibility for thrombosis
SE9303612D0 (sv) New use
WO2004100973A3 (en) Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases.
GR20000100283A (el) Μη-πεπτιδικοι μιμητες της δραστικης αλληλουχιας s42fllr46 του υποδοχεα της θρομβινης για την θεραπεια της θρομβωσης και του καρκινου
Samama et al. Miscellaneous: Dextran, Dermatan Sulfate, Low Molecular Weight Heparinoids (Org 10172), Pentosan Polysulfate (Sp54), Defibrinating Agents (Ancrod And Reptilase)
Meddahi et al. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Subramaniam et al. Direct thrombin inhibitors
Wieslander et al. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins
Nevarre et al. Hypercoagulability and the management of anticoagulant therapy in surgical patients: review and recommendations
Kornowski et al. Low molecular weight heparin (Fragmin®) prevents early reocclusion following femoral artery thrombolysis with rt-PA in rabbits
Bates et al. The new heparins

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20051018

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20060414

PC41 Official registration of the transfer of exclusive right

Effective date: 20151119